Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 13/20 | 0.86 |
| ▸ | BACE1 | P56817 | 1/20 | 0.71 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.71 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL264615 | 0.98 | LTA4H (0.83) | LTA4HBACE1PSMB1PSMB5HRH3 | |
| SCHEMBL5870409 | 0.98 | LTA4H (0.83) | LTA4HBACE1PSMB1PSMB5HRH3 | |
| SCHEMBL3951411 | 0.98 | LTA4H (0.83) | LTA4HBACE1PSMB1PSMB5HRH3 | |
| Bromide SCHEMBL4827747 | 0.96 | LTA4H (0.81) | LTA4HBACE1PSMB1PSMB5HRH3 | |
| Hydrochloric Acid SCHEMBL8475600 | 0.96 | LTA4H (0.81) | LTA4HBACE1PSMB1PSMB5HRH3 | |
| SCHEMBL14500223 | 0.94 | LTA4H (0.77) | LTA4HBACE1PSMB1PSMB5HRH3 | |
| SCHEMBL7141714 | 0.93 | LTA4H (1.00) | LTA4HPSMB1PSMB5HRH3 | |
| SCHEMBL492205 | 0.90 | HRH3 (0.84) | LTA4HHRH3KDM4EALDH1A1SMN1; SMN2 | |
| Anisole SCHEMBL28200949 | 0.90 | LTA4H (0.71) | LTA4HBACE1PSMB1PSMB5HRH3 | |
| SCHEMBL1899201 | 0.89 | LTA4H (1.00) | LTA4HBACE1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1060178-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER (US) | 2003-09-03 | — | — | EP | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-117285455-A | 2-benzoyl indole compounds and application thereof | 江苏开元药业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110071133-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100256394-A1 | METHOD FOR THE PREPARATION OF LASOFOXIFENE | ZENTIVA K.S. (CZ) | 2010-10-07 | — | — | US | disclosed |
| US-20100256394-A1 | METHOD FOR THE PREPARATION OF LASOFOXIFENE | ZENTIVA K.S. (CZ) | 2010-10-07 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-20030220377-A1 | Indole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2003-11-27 | — | — | US | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071133-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB2 | LTA4H 4014/4885BACE1 2722/4885PSMB1 3593/4885 |
| US-20100256394-A1 | METHOD FOR THE PREPARATION OF LASOFOXIFENE | SRD5A1, SRD5A2, CYP19A1 | LTA4H 2007/4885BACE1 1041/4885PSMB1 1800/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | LTA4H 2871/4885BACE1 1021/4885PSMB1 4495/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2984/4885BACE1 1020/4885PSMB1 4455/4885 |
| US-20030220377-A1 | Indole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | LTA4H 1023/4885BACE1 2233/4885PSMB1 4354/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | LTA4H 2557/4885BACE1 2321/4885PSMB1 3763/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | LTA4H 3261/4885BACE1 3676/4885PSMB1 1895/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2761/4885BACE1 1265/4885PSMB1 4621/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LTA4H 2761/4885BACE1 1265/4885PSMB1 4621/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | LTA4H 2093/4885BACE1 1596/4885PSMB1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.